The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
me change notification emails
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
Description of Modification
Modification to Previous
Funding Opportunity Number:
Apr 21, 2011
Apr 22, 2011
Original Closing Date for Applications:
Aug 23, 2011
Current Closing Date for Applications:
Aug 23, 2011
Sep 22, 2011
Funding Instrument Type:
Category of Funding Activity:
Science and Technology and other Research and Development
Expected Number of Awards:
Estimated Total Program Funding:
Military Medical Research and Development
Cost Sharing or Matching Requirement:
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Additional Information on Eligibility:
Dept. of the Army -- USAMRAA
The PCRP Idea Development Award mechanism was first offered in FY97. Since then, 5,700 Idea Development Award applications have been received, and 971 have been recommended for funding.The Idea Development Award supports new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to eliminating death and suffering from prostate cancer. Although groundbreaking research often involves a degree of risk, applications should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature. Due to this award�s emphasis on innovation, presentation of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Any preliminary data provided should be from the laboratory of the Principal Investigator (PI) or member(s) of the collaborating team.All applications for the Idea Development Award are highly recommended to address one of the FY11 PCRP overarching challenges. The PCRP seeks to fund projects from the wide spectrum of basic to clinical research; however, if the proposed project does not address one of the overarching challenges, the application should provide a description to justify how the project will nevertheless address a critical need in the field of prostate cancer research and/or patient care.PIs wishing to apply for funding for population-based studies should consider submitting an application for the FY11 PCRP Population-Based Research Award.Research involving human subject use is permitted under this funding opportunity, but is restricted to studies without clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. For more information on clinical research, a Human Subject Resource Document is provided at https://cdmrp.org/Program_Announcements_and_Forms/. PIs seeking funding for a clinical trial should consider submitting an application for the FY11 PCRP Clinical Trial Award.New Investigator Option: The FY11 Idea Development Award mechanism encourages applications from investigators in the early stages of their careers. The New Investigator Option is designed to allow applicants early in their faculty appointments, or in the process of developing independent research careers, to compete for funding separately from established investigators. Applications from New Investigators and Established Investigators will be peer- and programmatically reviewed in separate groups. PIs using the New Investigator Option are strongly encouraged to strengthen their applications by collaborating with investigators experienced in prostate cancer research and/or possessing other relevant expertise as demonstrated by a record of funding and publications. It is the responsibility of the applicant to describe how collaboration will augment the PI�s expertise and better address the research question.
Link to Additional Information
If you have difficulty accessing the full announcement
electronically, please contact:
The following files represent the modifications to this synopsis
with the changes noted within the documents. The list of files is
arranged from newest to oldest with the newest file representing the
current synopsis. Changed sections from the previous document are shown
in a light grey background.